Literature DB >> 17961566

Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks.

P C Ho1, P D Blumenthal, K Gemzell-Danielsson, R Gómez Ponce de León, S Mittal, O S Tang.   

Abstract

A combination of mifepristone and misoprostol is the regimen of choice for termination of pregnancy between 13 to 26 weeks. In many countries, mifepristone is still not available, and misoprostol has to be used alone. Many misoprostol-alone regimens have been reported in the literature with apparently good results. Most of the trials were conducted in pregnancies between 13 and 22 weeks. For this gestational period, we recommend the regimen of 400 microg of vaginal misoprostol every 3 h up to 5 doses, as it appears to be effective without excessive side effects or complications. There is inadequate data to recommend a regimen for the gestational period of 23 to 26 weeks but it is advisable to reduce the dose and frequency of administration of misoprostol. Common side effects of misoprostol-induced termination of pregnancy include gastrointestinal side effects, abdominal cramps, bleeding, fever and chills. Complications may include infection or rarely rupture of uterus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17961566     DOI: 10.1016/j.ijgo.2007.09.007

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  5 in total

Review 1.  Medical methods for mid-trimester termination of pregnancy.

Authors:  Hajo Wildschut; Marieke I Both; Suzanne Medema; Eeke Thomee; Mark F Wildhagen; Nathalie Kapp
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

2.  Misoprostol use in medical evacuation of spontaneous miscarriage: Pilot drug use evaluation study at the Women's Hospital in Qatar.

Authors:  Samah A ElSalem; Doua T AlSaad; Palli V Abdulrouf; Afif A Ahmed; Moza S AlHail
Journal:  Qatar Med J       Date:  2016-06-15

3.  Association between infection and fever in terminations of pregnancy using misoprostol: a retrospective cohort study.

Authors:  Tobias A J Nijman; Kevin G J A Voogdt; Pim W Teunissen; Patrick J Jp van der Voorn; Christianne J M de Groot; Petra C A M Bakker
Journal:  BMC Pregnancy Childbirth       Date:  2017-01-05       Impact factor: 3.007

4.  The effectiveness of using misoprostol with and without letrozole for successful medical abortion: A randomized placebo-controlled clinical trial.

Authors:  Elham Naghshineh; Zahra Allame; Faezah Farhat
Journal:  J Res Med Sci       Date:  2015-06       Impact factor: 1.852

5.  Comparison of sublingual and vaginal misoprostol for second-trimester pregnancy terminations.

Authors:  Forozan Milani; Seyede Hajar Sharami; Saeedeh Arjmandi
Journal:  J Family Reprod Health       Date:  2014-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.